Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms.

Gleitz HF, Liao AY, Cook JR, Rowlston SF, Forte GM, D'Souza Z, O'Leary C, Holley RJ, Bigger BW.

EMBO Mol Med. 2018 Jul;10(7). pii: e8730. doi: 10.15252/emmm.201708730.

2.

Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis.

Gleitz HF, Kramann R, Schneider RK.

J Pathol. 2018 Jun;245(2):138-146. doi: 10.1002/path.5078. Epub 2018 Apr 19. Review.

3.

Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.

Holley RJ, Ellison SM, Fil D, O'Leary C, McDermott J, Senthivel N, Langford-Smith AWW, Wilkinson FL, D'Souza Z, Parker H, Liao A, Rowlston S, Gleitz HFE, Kan SH, Dickson PI, Bigger BW.

Brain. 2018 Jan 1;141(1):99-116. doi: 10.1093/brain/awx311.

PMID:
29186350
4.

Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II.

Gleitz HF, O'Leary C, Holley RJ, Bigger BW.

PLoS One. 2017 Feb 16;12(2):e0172435. doi: 10.1371/journal.pone.0172435. eCollection 2017.

Supplemental Content

Loading ...
Support Center